Lamin B1 and its effects on blood stem cells and MDS
The role of lamin B1 in normal and myelodysplastic hematopoiesis
This project looks at whether lower levels of a protein called lamin B1 change how blood stem cells behave and contribute to myelodysplastic syndromes (MDS).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11309343 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are studying how the 3D organization of DNA in blood stem cells is shaped by lamin B1 and how changes in this protein may lead to MDS. The team will combine lab models, genomic mapping of DNA structure, and computer analysis to pinpoint genes and pathways affected when lamin B1 is reduced. They will focus on age-related changes and the common 5q deletion seen in some MDS patients to see if these changes drive abnormal blood cell development. Findings may come from a mix of patient-derived samples, cell or animal models, and large-scale genome data to build a clearer picture of disease mechanisms.
Who could benefit from this research
Good fit: Ideal candidates would be people with MDS or related blood disorders—especially those with a 5q deletion or age-related changes in blood production—who can provide samples or clinical information.
Not a fit: People with unrelated medical conditions or those needing immediate clinical treatment are unlikely to gain direct benefit from this basic research project.
Why it matters
Potential benefit: If successful, this work could reveal new biological targets or biomarkers that help prevent, diagnose, or treat MDS linked to lamin B1 loss.
How similar studies have performed: Previous research has connected nuclear lamins to genome organization and aging, but applying this specifically to MDS and the 5q-associated loss of LMNB1 is a newer and relatively untested approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Doulatov, Sergei — Columbia University Health Sciences
- Study coordinator: Doulatov, Sergei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.